Please login to the form below

Not currently logged in
Email:
Password:

Ultomiris

This page shows the latest Ultomiris news and features for those working in and with pharma, biotech and healthcare.

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.

Latest news

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH therapy with an NPV of $10.9bn.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics